Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03SVX
|
|||
| Former ID |
DAP001219
|
|||
| Drug Name |
Aliskiren
|
|||
| Synonyms |
Rasilez; SPP 100; Rasilez (TN); Tekturna (TN); Aliskiren (USAN/INN); (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Norvatis Phamaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H53N3O6
|
|||
| Canonical SMILES |
CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
|
|||
| InChI |
1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
|
|||
| InChIKey |
UXOWGYHJODZGMF-QORCZRPOSA-N
|
|||
| CAS Number |
CAS 173334-57-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980347, 14763777, 14886049, 17397362, 39475202, 46507474, 46509572, 51009124, 85176969, 87324641, 96099933, 103615727, 104178818, 114001043, 124897540, 126666078, 129435102, 134338459, 135916045, 137002989, 137227121, 140385193, 151991991, 152028160, 152258402, 160647239, 160964589, 162181387, 174006809, 175268617, 176485078, 177748803, 178101514, 179150066, 185997039, 187032771, 223393380, 223404348, 223435288, 223661693, 223720068, 224032552, 226775246, 242591596, 251916704, 251917943, 251970968, 252213891
|
|||
| ChEBI ID |
CHEBI:601027
|
|||
| ADReCS Drug ID | BADD_D00073 ; BADD_D00074 | |||
| SuperDrug ATC ID |
C09XA02
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensinogenase renin (REN) | Target Info | Inhibitor | [4] |
| KEGG Pathway | Renin-angiotensin system | |||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4812). | |||
| REF 2 | 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. | |||
| REF 3 | Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63. | |||
| REF 4 | Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patie... J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.